Gene Therapy for Rare Disorders 2017 Boston, Massachusetts, USA 24-26 April 2017

Description:
Gene Therapy for Rare Disorders 2017 is the only conference devoted to overcoming the clinical, manufacturing, regulatory and commercialization challenges holding back progress in this field.

Bringing together leading experts from innovative biotechs, large pharma, academia, regulatory authorities and key service provider companies, this conference will provide a comprehensive insight into the cutting edge progress of gene therapies combatting rare disease.

Rather than replicating broad academic cell and gene therapy meetings, you will learn from in-depth case studies detailing how gene therapies can become commercially successful in ophthalmic, CNS, hepatic, muscular and many other rare disorders.

Join your colleagues on this collaborative platform to accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.

Price:

Conference : USD 2699
Conference - Early Bird Price: USD 2599

Speakers: Michael Linden (VP, Gene Therapy, Pfizer), Lei Xu (Chief General Medicine Branch 2, Division of Clinical Evaluation and Pharmacology/Toxicology, OTAT, CBER, FDA), Lance Weed (VP, US Operations, UniQure), Seng Cheng (Global Head of Research, Rare Diseases, Sanofi), Sam Wadsworth (CSO, Dimension Therapeutics)

Venue details: Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States